Ask AI
ProCE Banner Activity

Identifying and Managing Treatment-Related Adverse Events in TGCT

Slideset

This downloadable slideset reviews the safety profiles of the FDA-approved CSF1R inhibitors pexidartinib and vimseltinib for tenosynovial giant cell tumor (TGCT). It also highlights common and clinically important adverse events, including hepatotoxicity, periorbital edema, rash, pruritus, gastrointestinal toxicities, and laboratory abnormalities, as well as differences between the agents. Patient counseling, laboratory monitoring, supportive care, treatment interruption, dose reduction, and permanent discontinuation strategies are also addressed to help healthcare professionals balance treatment efficacy with safety and quality of life in patients with TGCT.

Released: September 01, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Target Audience

This program is intended for oncologists, physician associates, nurses, nurse practitioners, clinical nurse specialists, pharmacists, and other healthcare professionals who care for patients with tenosynovial giant cell tumors.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement evidence-based strategies to monitor for and manage adverse events associated with CSF1R-targeted therapies, including hepatotoxicity and functional impact

Financial Disclosures

Primary Author

Emanuela Palmerini, MD, PhD: consultant/advisor/speaker: Daiichi Sankyo, Deciphera, EMD Serono, Servier, SpringWorks.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.